ELI LILLY & Co cotiza a 1166.51 USD y tiene una capitalización bursátil de $1.04T. En los últimos 12 meses ha facturado $79.7B con un margen de flujo de caja libre del 13.8%. Cotiza a 57.2 veces su flujo de caja libre (P/FCF) y a un PER de 38.9. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin…
| Periodo | 2026-10 | 2026-08 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $8.38 | $8.55 | $7.54 |
| Estimado | $7.16 | $6.58 | $6.79 | $6.91 |
| Sorpresa | — | +27.4% | +25.9% | +9.1% |
| Métrica | LLY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 83.0% | 57.0% | +26.0% |
| Operating Margin | — | -38.6% | — |
| Net Margin | 31.7% | -33.6% | +65.2% |
| FCF Margin | 13.8% | -13.9% | +27.6% |
| ROE | 77.8% | -40.4% | +118.2% |
| ROA | 18.4% | -32.0% | +50.4% |
| Current Ratio | 1.58 | 2.84 | -1.26 |
| Debt / Equity | 1.54 | 0.28 | +1.26 |